Department of Dermatology, University Hospital Erlangen, Erlangen, Germany.
Immunobiology. 2010 Sep-Oct;215(9-10):849-54. doi: 10.1016/j.imbio.2010.05.029. Epub 2010 Jun 4.
The cell surface protein CD83 belongs to the immunoglobulin super family and is highly expressed on mature dendritic cells (DCs). A membrane bound and a soluble form of CD83 (sCD83) have been described. Previously, the isolation of a purified recombinant sCD83 molecule from bacterial cultures using high pressure liquid chromatography was reported. This recombinant protein reduced DC-mediated T cell proliferation in vitro and displayed an inhibitory effect in the experimental autoimmune encephalomyelitis (EAE) model. When purifying sCD83 from bacteria, however, a lipopolysaccharide fraction is frequently co-isolated with the recombinant sCD83 protein. Moreover, the subsequent separation of sCD83 from contaminating LPS is usually accompanied by a considerable loss of soluble CD83. A further disadvantage of soluble CD83 expression in prokaryotic cells is the lack of functional glycosylation. To overcome these problems, we developed an alternative strategy to express sCD83 in eukaryotic human embryonic kidney (HEK) 293 T cells. Using this system, we showed that recombinant sCD83 was LPS-free and effectively glycosylated with all three asparagine residues at least partially involved. The functionality of the expressed sCD83 protein was examined using the mixed lymphocyte reaction (MLR) assay, demonstrating a reduced DC-mediated T cell proliferation as previously reported for the sCD83 protein purified from E. coli. Thus, a new protocol for efficient eukaryotic expression and purification of sCD83 was established, which might have several advantages compared to prokaryotic expression systems.
细胞表面蛋白 CD83 属于免疫球蛋白超家族,在成熟树突状细胞(DC)上高度表达。已经描述了膜结合形式和可溶性形式的 CD83(sCD83)。先前,已经报道了使用高压液相色谱从细菌培养物中分离纯化的重组 sCD83 分子。这种重组蛋白可降低体外 DC 介导的 T 细胞增殖,并在实验性自身免疫性脑脊髓炎(EAE)模型中显示出抑制作用。然而,在从细菌中纯化 sCD83 时,经常与重组 sCD83 蛋白一起共分离出脂多糖(LPS)部分。此外,随后从污染的 LPS 中分离 sCD83 通常伴随着可溶性 CD83 的大量损失。在原核细胞中表达可溶性 CD83 的另一个缺点是缺乏功能性糖基化。为了克服这些问题,我们开发了一种替代策略,在真核人胚肾(HEK)293 T 细胞中表达 sCD83。使用该系统,我们表明重组 sCD83 不含 LPS,并且至少部分涉及三种天冬酰胺残基的有效糖基化。通过混合淋巴细胞反应(MLR)测定检查表达的 sCD83 蛋白的功能,证明与先前从大肠杆菌中纯化的 sCD83 蛋白一样,DC 介导的 T 细胞增殖减少。因此,建立了一种新的有效真核表达和纯化 sCD83 的方案,与原核表达系统相比,它可能具有几个优势。